Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands

Shinshu University, Shonai, Nagano, Japan
Journal of Drug Targeting (Impact Factor: 2.74). 06/2007; 15(4):311-9. DOI: 10.1080/10611860701195510
Source: PubMed


Intravenous targeting of anticancer agents should improve both efficacy and therapeutic index. However, rational design of targeting constructs requires detailed definition of receptor targets and must take account of polarised tissue architecture that may restrict access to chosen receptors from the bloodstream. Bacteriophage biopanning provides a solution to this problem, identifying targeting sequences by functional selection rather than design, although reiterative panning in polarized human tumours has not previously been attempted. Here, we report an ex vivo, intra-arterial method for biopanning in freshly-resected human tumours, enabling reiterative selection of oligopeptide sequences capable of intravascular targeting to human colorectal tumours. Significant consensus was observed after two rounds of panning in tumours from different patients, and lead sequences demonstrated tumour targeting in samples from unrelated patients. This novel approach may be applicable to a wide range of settings, thus enabling iteration of consensus targeting sequences for tumour imaging and selective delivery of anticancer agents.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depending on their physiologic location and functional state, vascular endothelial cells express surface receptors differentially. Recognition of this molecular diversity is essential for the development of targeted therapies. Random phage display peptide libraries can be selected in vitro on recombinant proteins or on intact cells. After systemic injection, selection can be performed in animals and humans in vivo for the isolation of ligands for tissue-specific receptors. For the screening of libraries on intact cells or tissues, no a priori knowledge of the targeted receptor is needed, as the recovered peptide ligands can identify their corresponding receptors. Furthermore, the isolated peptides can be used to target therapeutic chemicals, biologicals, gene therapy vectors, or diagnostic compounds to specific tissues in vivo. Protocols for the screening of phage libraries in these three settings--on proteins, on cells in vitro and in the living animal--are described in this chapter.
    No preview · Article · Feb 2008 · Methods in enzymology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of intravascular conjugates that efficiently deliver genes or drugs to tumors is limited by the lack of efficacious targeting ligands. Small targeting peptides, such as those iterated by phage display technology, offer enormous potential for these applications. The majority of reports published to date have focused on the identification of peptides isolated for their ability to bind to human cancer cell lines in vitro, and have failed to account for the loss of polarization and de-differentiation of such cells from their in vivo state. Here, we report a novel approach for the identification of peptides capable of binding specifically to cancer cells derived from clinically resected human colon cancer. In this strategy, laser capture microdissection (LCM) is performed on a surgically resected colon cancer specimen to separate only cancer cells from the specimen. Subsequently, biopanning was performed on the LCM-selected colon cancer cells to identify peptide sequences that bound specifically to them. A peptide containing the SPT motif was selected as the most promising consensus sequence binding specifically to the LCM-selected colon cancer cells. Phage clones displaying the SPT motif demonstrated 9-fold higher binding to colon cancer cells derived from a patient than insertless phage (p < 0.05), while, recovery of the SPT phage from the colon cancer cell lines DLD-1 and HCT-15 was 7-fold higher than that of the control insertless phage (p < 0.05). The binding of SPT phage to colon cancer cells from the patient was confirmed by immunofluorescence. Additionally, a synthesized SPT-containing peptide (SPTKSNS) showed binding activity in the absence of mitogenic effects on colon cancer cells in vitro. In summary, we have introduced LCM into a biopanning procedure and identified a small peptide that binds preferentially to colon cancer cells derived from a clinically resected sample. This procedure could be applicable for the design of customized cancer cell targeting methodologies using clinical biopsy samples from human subjects.
    No preview · Article · Jul 2008 · Journal of Drug Targeting
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter contains sections titled: IntroductionOverview of Cancer-Targeting Ligand-Drug ConjugatesCancer-Targeting LigandsLinkersExamples of Cancer-Targeting Ligand-Drug ConjugatesConclusions and PerspectivesAcknowledgmentsReferences
    No preview · Chapter · Dec 2011
Show more